[혁신형 제약기업 점검]③ 팜젠사이언스, 약가방어로 체질전환 시간 확보

Pharmgen Science's strategic transition from generic-drug-dependent operations to R&D-driven innovation reflects how Korean pharmaceutical pricing reforms are reshaping industry business models. The company pursues innovation certification to mitigate revenue loss from price cuts while funding critical clinical trials for lead candidates RD1303 and RD1305. This transformation illustrates the growing pharmaceutical sector shift toward innovation-based competition incentivized by government policy.